Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, comments on preliminary findings from a Phase II single-arm, open-label trial (NCT04762160) of tazemetostat, an enhancer of zeste homolog 2 (EZH2) inhibitor, with rituximab in patients with relapsed/refractory follicular lymphoma (FL). Five patients have been enrolled so far and tazemetostat with rituximab have shown initial promise in patients, with further data yet to be published. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.